

PRESS RELEASE

Hansa Biopharma: Issue and repurchase of class C shares for incentive programs

Lund September 9, 2022. The board of directors for Hansa Biopharma AB (publ) has today resolved to issue 850,769 new class C shares and to immediately thereafter repurchase such 850,769 issued class C shares, for the purpose of the long term incentive programs based on performance-based share rights adopted by the annual general meeting held on 30 June 2022 (“Share Rights Program 2022”), the long term incentive programs based on employee stock options adopted by the annual general meeting held on 30 June 2022 (“Option Program 2022”) and/or previously adopted and outstanding incentive programs approved by the annual general meetings held 2018, 2019, 2020 and 2021 (the “Outstanding Incentive Programs”). Today’s resolution by the board of directors was passed based on the authorisations granted by the annual general meeting held on 30 June 2022.

Svenska Handelsbanken AB (publ) will subscribe for all issued class C shares at a subscription price of SEK one (1) per share. All 850,769 issued class C shares will be repurchased by Hansa Biopharma AB (publ) at a purchase price of SEK one (1) per share. Following the share issue, the share capital will increase by SEK 850,769. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

The purpose of the share issue and repurchase is to ensure delivery of shares to participants in, as well as to secure potential social contributions arising as a result of, the Share Rights Program 2022, the Option Program 2022 and/or the Outstanding Incentive Programs. The class C shares will be converted to ordinary shares before delivery to the participants in the programs.

Hansa Biopharma AB (publ) currently holds 1,747,243 class C shares and will, following the repurchase of the new 850,769 issued class C shares, hold all 2,598,012 class C shares in the company.

--ENDS--

For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving, and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy, and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.